Allogeneic memory NK cell therapy exhibits excellent tumor resistance or can overcome solid tumor obstruction

WU-NK-101 is an allogeneic memory NK cell therapy developed by Wugen using its proprietary MonetaTM platform, with a unique, more potent anti-tumor activity and cytokine-induced memory-like (CIML) phenotype

In addition, WU-NK-101 in combination with monoclonal antibodies showed strong anti-tumor activity, which was manifested in strong

Overall, these data suggest that WU-NK-101 may overcome many of the limitations of current cell therapies and show great potential

Nottingham Trent University's Professor of Cancer Immunotherapy, M.

Winning with allogeneic cell therapy

Although Wugen is a clinical-stage biotechnology company, Wugen has been favored by many capitals since its debut, and in March 2021, Wugen reached an exclusive cooperation with Chentai Pharmaceutical, and in July 2021, Wugen completed a $172 million Series B financing, which is a relatively outstanding result for a new talent, and the achievement of these results has a greater connection with

By analyzing Wugen's pipeline layout, it can be found that in addition to the layout of NK cell therapy, Wugen also laid out CAR-T therapy, but whether it is NK cell therapy or CAR-T therapy, Wugen's pipeline layout is allogeneic cell therapy

Its CAR-T cell platform is designed to remove target antigens from the surface of engineered CAR-T cells from healthy donor T cells, preventing CAR-T cells from killing themselves while ensuring they can kill tumor cells, and removing T cell surface receptors from healthy donors without the risk of
life-threatening graft-versus-host disease (GvHD).

▲CAR-T cell platform (Source: Wugen's official website)

Wugen laid out three pipelines through these two technology platforms, in addition to the WU-NK-101 mentioned above, the other two pipelines are WU-CART-007 and WU-NK-201
.

▲Wugen pipeline (Source: Wugen official website)

WU-CART-007 is an allogeneic, ready-to-use CD7-targeting CAR-T cell therapy designed to overcome the technical challenges
of using CAR-T cells to treat CD7+ hematologic malignancies.

The product knocks out CD7 and T cell receptor α constant regions (TRACs) on the surface of CAR-T cells through Wugen's proprietary technology platform, which not only prevents CAR-T cell cannibalism but also reduces the risk of graft-versus-host disease (GvHD), effectively overcoming some limitations
of CD7 CAR-T.

Preclinical study data show that WU-CART-007 has good safety and exhibits good CD7-specific antitumor activity
in vivo and in vitro.

In March 2022, the first patient administration of the first patient administration
of the Phase 1/2 clinical trial of the therapy for the treatment of R/R T-ALL/LBL was completed.

In July 2022, the therapy was recognized
by the FDA as a fast-track and rare pediatric disease.

WU-NK-201, similar to WU-NK-101, is an allogeneic memory NK therapy that is undergoing early preclinical testing
of solid tumors.

In addition to Wugen, allogeneic therapy has also become a hot spot in the research of many cell therapy companies, according to Nature data, the number of allogeneic cell therapy pipelines has increased from 399 in 2021 to 531 in 2022, a growth rate of 33%.


In the same period, the number of autologous cell therapies increased from 825 to 1019, with a growth rate of 23%.


Allogeneic cell therapy is growing faster than autologous CAR-T therapy
.

epilogue

Allogeneic cell therapy can reduce costs, shorten patient waiting time, apply a wider range of patients, and are not limited by the distribution of treatment centers, so it can solve the main problems in the current clinical application of autologous CAR-T therapy, and is expected to become the choice of more patients, which is an important development direction
of future cell therapy.

In today's intra-cell therapy, allogeneic cell therapy is also a major difference in the layout of enterprise cell therapy, which can effectively help enterprises stand out from
many cell therapy companies.

Resources:

1.
Wugen official website

——List of recent hot events——

▼On September 21, Merck China Biosafety Testing Center was opened